NASDAQ · REVB
Healthcare · Biotechnology
$1.03
Up+$0.08 (+7.85%)
Updated Aug 28, 2026, 12:05 PM
SID Score
2.7/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
REVB closed at $1.03 after 21 trading sessions, up 3.48% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 27, 2026 | $0.9718 | $1.03 | $0.9552 | $1.03 | 20.97K |
| Aug 26, 2026 | $0.9801 | $1.01 | $0.95 | $0.955 | 36.58K |
| Aug 25, 2026 | $1.09 | $1.10 | $0.91 | $1.00 | 200.06K |
| Aug 24, 2026 | $1.10 | $1.12 | $1.0604 | $1.10 | 49.71K |
| Aug 21, 2026 | $1.10 | $1.10 | $1.06 | $1.09 | 9.06K |
| Aug 20, 2026 | $1.12 | $1.14 | $1.07 | $1.07 | 22.18K |
| Aug 19, 2026 | $1.16 | $1.20 | $1.09 | $1.11 | 166.47K |
| Aug 18, 2026 | $1.145 | $1.16 | $1.07 | $1.11 | 75.99K |
| Aug 17, 2026 | $1.09 | $1.15 | $1.05 | $1.15 | 66.94K |
| Aug 14, 2026 | $1.14 | $1.14 | $1.0339 | $1.049 | 31.38K |
| Aug 13, 2026 | $1.11 | $1.12 | $1.10 | $1.11 | 8.08K |
| Aug 12, 2026 | $1.10 | $1.125 | $1.10 | $1.11 | 4.62K |
| Aug 11, 2026 | $1.145 | $1.145 | $1.10 | $1.13 | 15.22K |
| Aug 10, 2026 | $1.18 | $1.2173 | $1.12 | $1.13 | 34.53K |
| Aug 7, 2026 | $1.03 | $1.20 | $1.03 | $1.14 | 25.57K |
| Aug 6, 2026 | $1.13 | $1.1521 | $1.12 | $1.12 | 6.05K |
| Aug 5, 2026 | $1.14 | $1.1804 | $1.125 | $1.15 | 22.68K |
| Aug 4, 2026 | $1.07 | $1.15 | $1.0451 | $1.13 | 33.68K |
| Aug 3, 2026 | $0.9976 | $1.029 | $0.975 | $1.02 | 30.33K |
| Jul 31, 2026 | $1.00 | $1.01 | $0.95 | $0.95 | 23.66K |
| Jul 30, 2026 | $0.9999 | $1.00 | $0.9908 | $0.9954 | 32.1K |
The latest Smart Investors Daily articles mentioning REVB.
REVB research
Company profile and research snapshot.
Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Feb 14, 2023 | Roth MKM | Buy | — |
| Feb 17, 2022 | Roth Capital | Buy | — |
No generated briefing is available yet.
ChartMill · Aug 6, 2026
Revelation Biosciences posts narrow Q2 miss, but stock surges 254% on AKI pipeline progress, advisory board expansion, and Phase 2/3 trial startup momentum.
Benzinga · Aug 3, 2026
The independent market assessment evaluated Gemini for the treatment of Stage 2 and Stage 3 Acute Kidney Injury (AKI), a major cause of morbidity and mortality, which according to publicly available data affects more
Benzinga · Feb 26, 2026
Revelation Biosciences (NASDAQ:REVB) reported quarterly losses of $(1.65) per share which missed the analyst consensus estimate of $(0.96) by 71.88 percent. This is a 97.24 percent increase over losses of $(59.76) per
Benzinga · Jan 30, 2026
Revelation Biosciences, Inc. 4,272,500 Shares of Common Stock This prospectus relates to the resale, from time to time, of up to 4,272,500 shares of common stock, par value $0.001 per share, by the selling
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning REVB.
